Triple
T18644847
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Novo Nordisk |
E455777
|
entity |
| Predicate | majorProduct |
P7216
|
FINISHED |
| Object |
Saxenda
Saxenda is a prescription weight-loss medication (liraglutide) developed by Novo Nordisk that helps manage obesity by mimicking the GLP-1 hormone to reduce appetite.
|
E1336623
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Saxenda | Statement: [Novo Nordisk, majorProduct, Saxenda]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Saxenda Context triple: [Novo Nordisk, majorProduct, Saxenda]
-
A.
Ozempic
Ozempic is a prescription semaglutide medication primarily used to improve blood sugar control in adults with type 2 diabetes and widely known for its weight-loss effects.
-
B.
Mounjaro
Mounjaro is a prescription medication (tirzepatide) used primarily to improve blood sugar control in adults with type 2 diabetes and increasingly known for its weight-loss effects.
-
C.
Trulicity
Trulicity is a prescription GLP-1 receptor agonist medication used to improve blood sugar control in adults with type 2 diabetes.
-
D.
Rybelsus
Rybelsus is an oral semaglutide medication used to improve blood sugar control in adults with type 2 diabetes.
-
E.
Farxiga
Farxiga is a prescription SGLT2 inhibitor medication used primarily to treat type 2 diabetes and reduce the risk of cardiovascular and kidney complications.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Saxenda Triple: [Novo Nordisk, majorProduct, Saxenda]
Generated description
Saxenda is a prescription weight-loss medication (liraglutide) developed by Novo Nordisk that helps manage obesity by mimicking the GLP-1 hormone to reduce appetite.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Saxenda Target entity description: Saxenda is a prescription weight-loss medication (liraglutide) developed by Novo Nordisk that helps manage obesity by mimicking the GLP-1 hormone to reduce appetite.
-
A.
Ozempic
Ozempic is a prescription semaglutide medication primarily used to improve blood sugar control in adults with type 2 diabetes and widely known for its weight-loss effects.
-
B.
Mounjaro
Mounjaro is a prescription medication (tirzepatide) used primarily to improve blood sugar control in adults with type 2 diabetes and increasingly known for its weight-loss effects.
-
C.
Trulicity
Trulicity is a prescription GLP-1 receptor agonist medication used to improve blood sugar control in adults with type 2 diabetes.
-
D.
Rybelsus
Rybelsus is an oral semaglutide medication used to improve blood sugar control in adults with type 2 diabetes.
-
E.
Farxiga
Farxiga is a prescription SGLT2 inhibitor medication used primarily to treat type 2 diabetes and reduce the risk of cardiovascular and kidney complications.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8d38ea1e88190997e9b231190ba6f |
completed | April 10, 2026, 10:40 a.m. |
| NER | Named-entity recognition | batch_69e5500c36188190bfdd7aca73f3c006 |
completed | April 19, 2026, 9:58 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_6a051718605881909af06e9ee0c886ef |
completed | May 14, 2026, 12:28 a.m. |
| NEDg | Description generation | batch_6a05192a654481908235ea8e16150c9b |
completed | May 14, 2026, 12:36 a.m. |
| NED2 | Entity disambiguation (via description) | batch_6a05199a9abc8190baba3e1ba422fd03 |
completed | May 14, 2026, 12:38 a.m. |
Created at: April 10, 2026, 11:47 a.m.